While no significant differences were observed in overall survival (OS) with respect to NRP2 expression (p = 0.21; Figure 6A), patients with high NRP2 expression exhibited significantly worse distant metastasis-free survival (DMFS) rates than those with low NRP2 expression (p = 0.0092; Figure 6B), suggesting the role of NRP2 as a novel biomarker for predicting recurrence in breast cancer patients. This evidence concerns the gene NRP2 and breast carcinoma.